Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D
Kazumasa Komura, … , Christopher J. Sweeney, Philip W. Kantoff
Kazumasa Komura, … , Christopher J. Sweeney, Philip W. Kantoff
Published June 4, 2018
Citation Information: J Clin Invest. 2018;128(7):2979-2995. https://doi.org/10.1172/JCI96769.
View: Text | PDF
Research Article Genetics Oncology

ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D

  • Text
  • PDF
Abstract

Epigenetic modifications control cancer development and clonal evolution in various cancer types. Here, we show that loss of the male-specific histone demethylase lysine-specific demethylase 5D (KDM5D) encoded on the Y chromosome epigenetically modifies histone methylation marks and alters gene expression, resulting in aggressive prostate cancer. Fluorescent in situ hybridization demonstrated that segmental or total deletion of the Y chromosome in prostate cancer cells is one of the causes of decreased KDM5D mRNA expression. The result of ChIP-sequencing analysis revealed that KDM5D preferably binds to promoter regions with coenrichment of the motifs of crucial transcription factors that regulate the cell cycle. Loss of KDM5D expression with dysregulated H3K4me3 transcriptional marks was associated with acceleration of the cell cycle and mitotic entry, leading to increased DNA-replication stress. Analysis of multiple clinical data sets reproducibly showed that loss of expression of KDM5D confers a poorer prognosis. Notably, we also found stress-induced DNA damage on the serine/threonine protein kinase ATR with loss of KDM5D. In KDM5D-deficient cells, blocking ATR activity with an ATR inhibitor enhanced DNA damage, which led to subsequent apoptosis. These data start to elucidate the biological characteristics resulting from loss of KDM5D and also provide clues for a potential novel therapeutic approach for this subset of aggressive prostate cancer.

Authors

Kazumasa Komura, Yuki Yoshikawa, Teppei Shimamura, Goutam Chakraborty, Travis A. Gerke, Kunihiko Hinohara, Kalyani Chadalavada, Seong Ho Jeong, Joshua Armenia, Shin-Yi Du, Ying Z. Mazzu, Kohei Taniguchi, Naokazu Ibuki, Clifford A. Meyer, Gouri J. Nanjangud, Teruo Inamoto, Gwo-Shu Mary Lee, Lorelei A. Mucci, Haruhito Azuma, Christopher J. Sweeney, Philip W. Kantoff

×

Figure 7

Synthetic lethal approach exploiting DNA-replication stress by the loss of KDM5D.

Options: View larger image (or click on image) Download as PowerPoint
Synthetic lethal approach exploiting DNA-replication stress by the loss ...
(A) Data on growth of cells treated with VE822 in LNCaP sh-control, sh-KDM5D#1, and sh-KDM5D#3. Cells were treated with the indicated concentrations of VE822 for 72 hours. The inhibitory effect on cell growth is presented as a relative value (mean ± SD) compared with control as 100%. The results of 3 independent experiments are shown. (B) Nuclear fractions and total cell lysates were collected in LNCaP sh-control, sh-KDM5D#1, and sh-KDM5D#3 after 24 hours of treatment with DMSO or 5 μM VE822 and subjected to immunoblotting with the indicated antibodies. (C) Nuclear fraction was collected in VCaP cells with si-control and si-KDM5D and subjected to immunoblotting using indicated antibody including KDM5D, ATR, p-ATR, CHK1, p-CHK1, and H3 (loading control). (D) VCaP cell line with or without si-KDM5D was stained by immunofluorescence for the replicative stress markers, including p-RPA2 and p-rH2AX. (E) Data on growth of cells treated with VE822 in VCaP cells using si-control or si-KDM5D. Cells were treated with the indicated concentrations of VE822 for 72 hours. The inhibitory effect on cell growth is presented as a relative value (mean ± SD) compared with control as 100%. The results of 3 independent experiments are shown. (F) Nuclear fractions and total cell lysates were collected in VCaP cells using si-control or si-KDM5D after 24 hours of treatment with DMSO or 5 μM of VE822, and subjected to immunoblotting with the indicated antibodies.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts